NF-κBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1β-induced and TNF-α-induced chondrocytes

 

 Lianxu Chen Ph.D.^a, Hongti Jia Ph.D.^b, Changlong Yu Ph.D.^a,* 

^a Institute of Sports Medicine,Peking University Third Hospital, No.49, North Garden Road, Haidian District, Beijing 100083, P.R.China北京大学第三医院运动医学科陈连旭

^b The Department of Biochemistry and Molecular Biology, Peking University School of Basic Medicial Science, Beijing 100083, P.R.China 

Objective: Small interfering RNA (siRNA) triggers RNA interference in mammalian somatic cells. Nuclear factor kappa B (NF-κB) is a transcription factor that is implicated in inflammation and immune activation. This study was to use NF-κBp65-specific siRNA to inhibit the expression of genes of cyclooxygenase-2 (COX-2), nitric oxide synthase-2 (NOS-2) and matrix metalloproteinase-9 (MMP-9), which is paralleled with the initiation and progression of cartilage lesions in osteoarthritis (OA) model, in induced chondrocytes, and therefore to explore a new gene therapy for OA. 

Methods: Western blot and reverse transcription polymerase chain reaction (RT-PCR) were performed to optimize the silencing effects of NF-κBp65-specific siRNA in cultured rat chondrocytes, and then to determine the expression of COX-2, NOS-2 and MMP-9 in induced chondrocytes. The activation of NF-κB was determined by electrophoretic mobility shift assay (EMSA). Western blot and RT-PCR were subjected to densitometric analysis and then band intensities were also determined. 

Results: The NF-κBp65-specific siRNA inhibited the expression of NF-κBp65 and activation of NF-κB, reducing siginificantly the expression of COX-2, NOS-2 and MMP-9 induced by interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in cultured chondrocytes. 

Conclusions: NF-κBp65-specific siRNA can inhibit the expression of COX-2, NOS-2 and MMP-9 in IL-1β-induced and TNF-α-induced chondrocytes. This suggests that NF-κBp65-specific siRNA has potential to be a useful preventive and therapeutic agent for OA at early stage. 

Key words: siRNA, NF-κBp65, Articular chondrocytes, COX-2, NOS-2, MMP-9,